Whalesbook
Financial Performance
Sanofi India reported a 14% decline in first-quarter net profit, reaching ₹102.6 crore against ₹119.5 crore a year prior. Revenue saw a 4.9% decrease, falling to ₹472.3 crore from ₹535.9 crore in the corresponding period.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) dropped by 16.9% to ₹142.8 crore, with the EBITDA margin contracting to 30.2% from 32.1% a year ago. The company attributed the overall quarterly results to transactions linked to partnership transitions, which created a stable base in cardiovascular, oral anti-diabetes, and central nervous system segments but impacted top-line performance.
Portfolio Strengths and Outlook
Despite the financial headwinds, Sanofi India's domestic insulin portfolio delivered robust double-digit growth for the second consecutive quarter, reinforcing its strong position in the diabetes injectable market. Managing Director Deepak Arora highlighted insulin's continued essential role in comprehensive diabetes care, validated by the company's sequential and year-on-year growth in this segment.
Arora expressed confidence that strategic partnerships will serve as catalysts for growth, enhancing the company's commercial footprint and market penetration. Sanofi India continues to focus on efficiency improvements through targeted market initiatives and refined go-to-market strategies, while export sales show signs of stabilization amidst geopolitical conditions.